Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.
作者信息
Chakravarty Rubel, Lan Xiaoli, Chakraborty Sudipta, Cai Weibo
机构信息
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
出版信息
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1844-1847. doi: 10.1007/s00259-023-06178-4.
Abstract
摘要
相似文献
1
Astatine-211 for PSMA-targeted α-radiation therapy of micrometastatic prostate cancer: a sustainable approach towards precision oncology.
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1844-1847. doi: 10.1007/s00259-023-06178-4.
2
Targeted α-therapy using astatine (At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):849-858. doi: 10.1007/s00259-022-06016-z. Epub 2022 Nov 8.
3
Patterns of relapse as determined by Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
Strahlenther Onkol. 2018 Apr;194(4):303-310. doi: 10.1007/s00066-017-1231-9. Epub 2017 Nov 13.
4
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1.
5
PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Int J Mol Sci. 2022 Jan 21;23(3):1158. doi: 10.3390/ijms23031158.
6
Manual on the proper use of the At-labeled PSMA ligand ([At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition).
Ann Nucl Med. 2024 May;38(5):329-336. doi: 10.1007/s12149-024-01916-6. Epub 2024 Mar 28.
7
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
J Nucl Med. 2016 Oct;57(10):1569-1575. doi: 10.2967/jnumed.116.174300. Epub 2016 May 26.
8
PSMA PET and Radionuclide Therapy in Prostate Cancer.
Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3.
9
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357.
10
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27.
引用本文的文献
1
The Different Strategies for the Radiolabeling of [At]-Astatinated Radiopharmaceuticals.
Pharmaceutics. 2024 May 30;16(6):738. doi: 10.3390/pharmaceutics16060738.
2
In vivo stable At-labeled prostate-specific membrane antigen-targeted tracer using a neopentyl glycol structure.
EJNMMI Radiopharm Chem. 2024 Jun 17;9(1):48. doi: 10.1186/s41181-024-00278-8.
3
Actinium-225 targeted alpha particle therapy for prostate cancer.
Theranostics. 2024 May 11;14(7):2969-2992. doi: 10.7150/thno.96403. eCollection 2024.
4
A third generation PSMA-targeted agent [At]YF2: Synthesis and in vivo evaluation.
Nucl Med Biol. 2024 Jul-Aug;134-135:108916. doi: 10.1016/j.nucmedbio.2024.108916. Epub 2024 May 1.
5
Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm.
Chem Biomed Imaging. 2023 Nov 21;2(1):4-26. doi: 10.1021/cbmi.3c00092. eCollection 2024 Jan 22.
6
Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future.
Curr Radiopharm. 2024;17(1):7-13. doi: 10.2174/0118744710262325231025075638.
本文引用的文献
1
Comparison of PSMA-based F-DCFPyL PET/CT and pelvic multiparametric MRI for lesion detection in the pelvis in patients with prostate cancer.
Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):166-179. eCollection 2022.
2
PSMA-based F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?
Am J Nucl Med Mol Imaging. 2022 Dec 15;12(6):195-200. eCollection 2022.
3
Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts.
Front Med (Lausanne). 2022 Dec 6;9:1060922. doi: 10.3389/fmed.2022.1060922. eCollection 2022.
4
Targeted α-therapy using astatine (At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):849-858. doi: 10.1007/s00259-022-06016-z. Epub 2022 Nov 8.
5
Hematologic toxicity profile and efficacy of [Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2022 Aug;49(10):3581-3592. doi: 10.1007/s00259-022-05778-w. Epub 2022 Apr 6.
6
Global experience with PSMA-based alpha therapy in prostate cancer.
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):30-46. doi: 10.1007/s00259-021-05434-9. Epub 2021 Jun 26.
7
Synthesis of [At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution.
Sci Rep. 2021 Jun 21;11(1):12982. doi: 10.1038/s41598-021-92476-6.
8
Production, purification and availability of At: Near term steps towards global access.
Nucl Med Biol. 2021 Sep-Oct;100-101:12-23. doi: 10.1016/j.nucmedbio.2021.05.007. Epub 2021 Jun 10.
9
An Improved At-Labeled Agent for PSMA-Targeted α-Therapy.
J Nucl Med. 2022 Feb;63(2):259-267. doi: 10.2967/jnumed.121.262098. Epub 2021 Jun 4.
10
Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Prostate. 2021 Jun;81(9):580-591. doi: 10.1002/pros.24137. Epub 2021 Apr 27.
Zotero 插件